About Cerevel Therapeutics
Cerevel Therapeutics is a Healthcare company based in Boston (United States) founded in 2018, and was acquired by AbbVie in December 2023. Therapeutics for neurological and neuropsychiatric disorders are developed. The company has 199 employees. Its chief executive, as recorded, is Tony Coles. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its competitors include Kriya Therapeutics, Sana Biotechnology and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Cerevel Therapeutics was founded in 2018 and is headquartered in Boston, United States. Focus is placed on the biotechnology sector, where small-molecule therapeutics are advanced for neurological and neuropsychiatric conditions. A dopamine D1 agonist and GABA A positive modulator are targeted at Parkinsons Disease. CVL-871 addresses dementia-related apathy, and CVL-865 is directed toward epilepsy and anxiety disorders.
- Headquarters Boston, United States
- Employees 199
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website cerevel.com
- Social LinkedIn X Facebook
- Acquired by AbbVie (Dec 2023)
Funding Insights of Cerevel Therapeutics
- Total Rounds 1
- Investors Count 2
All 1 funding rounds of Cerevel Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | Series D | – | – |
3 investors in total: 3 institutional.
Investors in Cerevel Therapeutics
Cerevel Therapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie, NovaQuest Capital Management and Bain Capital Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm focused on life science and healthcare companies | novaquest.com | Raleigh, United States | ||
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | abbvie.com | Chicago, United States |
Investor details for Cerevel Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cerevel Therapeutics
1491 people are tracked at Cerevel Therapeutics (744 in leadership, 12 in board & advisors, 735 in team); the tracked headcount is 199.
| Name | Role | Group |
|---|---|---|
Tony Coles | CEO | Leadership |
Dana Overbey | Global Sr Director Vendor Management Office And Technology Asset Management | Leadership |
Lauren Yarnell | Executive Assistant To The Svp, Abbvie & President, Specialty & U.s. Therapeutics Operations | Leadership |
Martin Hayes | Chief Of Staff, Global Neuroscience & Ophthalmology Research | Leadership |
Brad Pignatello | Director Ii, Payer Strategy Eye Care - US Market Access | Leadership |
Bruce Dannan | Director, Commercial Business Technology | Leadership |
Aimee Marx | Head Of Marketing US Patient Services | Leadership |
Bardia Akbari | Vice President - Development Operations Oncology | Leadership |
Sarah Cantor | Marketing Director - Access, Advocacy, And Non-retail | Leadership |
Nisha Patel Burns | Senior Vice President, AbbVie and President, Specialty and U.S. Therapeutics Operations | Leadership |
Michael Schaffer | Director Ii, Neurology Franchise Lead | Leadership |
Mohamed Haytham | General Manager - North Africa | Leadership |
Amanda Arlis | Director | Leadership |
Katie Stromsborg | Director Of Business Training And Development | Leadership |
Ana Alzugaray Beitia | CFO Spain | Leadership |
Alicia Subasinghe | Senior Director, Patient Advocacy | Leadership |
April Hughes | Associate Marketing Director, Immunology | Leadership |
Paula Lima | Oncology Patient (consumer) Marketing Associate Director | Leadership |
Cormac Dalton | Vice President Sterile Manufacturing | Leadership |
Edgar Torres | Director, Transformation | Leadership |
1471 more people are available in the full profile.
Complete people profiles for Cerevel Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cerevel Therapeutics
3 dated milestones of Cerevel Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Cerevel Therapeutics is founded.
- Funding First funding round.
- Exit Acquired by AbbVie.
Competitors of Cerevel Therapeutics
Cerevel Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Cerevel Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Cerevel Therapeutics (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cerevel Therapeutics
Complete news archive for Cerevel Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cerevel Therapeutics
Cerevel Therapeutics was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Cerevel Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Tony Coles is the CEO of Cerevel Therapeutics, as recorded in our data.
Cerevel Therapeutics has 199 employees.
Cerevel Therapeutics was founded in 2018 and is headquartered in Boston, United States. Focus is placed on the biotechnology sector, where small-molecule therapeutics are advanced for neurological and neuropsychiatric conditions. A dopamine D1 agonist and GABA A positive modulator are targeted at Parkinsons Disease. CVL-871 addresses dementia-related apathy, and CVL-865 is directed toward epilepsy and anxiety disorders.
Cerevel Therapeutics's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.
Cerevel Therapeutics has 3 investors. Key investors include AbbVie, NovaQuest Capital Management, and Bain Capital Life Sciences.
Yes. Cerevel Therapeutics was acquired by AbbVie in December 2023.